President Donald Trump’s executive order on May 12 instituting most-favored-nation (MFN) pricing of prescription drugs sought to ensure that Americans would pay no more than the lowest price charged in similar countries. Using an MFN model to set U.S. drug prices would have a considerable positive effect on American consumers, employers and governments.
As pointed out in “Solving the U.S. Drug Conundrum,” which I co-authored with my company co-founder Pascal Orliac, Americans suffer from sky-high drug prices. They pay between 4.5 and 4.8 times higher drug prices at the manufacturer level compared to the French or British.
